Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company focused on developing precision medicine approaches to restore vascular integrity in critically ill patients, particularly those suffering from septic shock
Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company focused on developing precision medicine approaches to restore vascular integrity in critically ill patients, particularly those suffering from septic shock. Their lead product candidate, Enibarcimab, is a first-in-class monoclonal antibody targeting the vasoprotective peptide Adrenomedullin.